Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Am J Clin Pathol. 2012 Feb;137(2):220-6. doi: 10.1309/AJCPPT93VZMAREHK.
Flow cytometric T-cell receptor V(β) repertoire analysis (TCR-V(β)-R) is a sensitive method to detect T-cell clonality; however, its implementation in low-cellularity specimens has not been established. We developed a strategy to use TCR-V(β)-R in cerebrospinal fluid (CSF) and fine-needle aspirate (FNA) specimens. Initially, full TCR-V(β)-R was evaluated in diagnostic/screening specimens from 8 patients with T-cell neoplasia to determine tumor-specific TCR-V(β) protein expression. Subsequently, an abbreviated, patient-specific TCR-V(β)-R evaluation was performed in 17 paucicellular specimens from the patients (8 CSF, 9 FNA) for staging and monitoring of minimal residual disease (MRD). A single cocktail containing 3 anti-V(β) antibodies (1 tumor-specific and 2 negative controls) in combination with other antibodies chosen to help gate on atypical T cells is highly sensitive and specific for detecting low-level neoplastic T-cell involvement in paucicellular specimens. This TCR-V(β)-R strategy is valuable in staging and evaluating MRD in patients with T-cell non-Hodgkin lymphoma.
流式细胞术 T 细胞受体 V(β)谱分析(TCR-V(β)-R)是一种敏感的方法,可用于检测 T 细胞克隆性;然而,其在低细胞标本中的应用尚未确定。我们开发了一种在脑脊液(CSF)和细针抽吸(FNA)标本中使用 TCR-V(β)-R 的策略。最初,在 8 例 T 细胞肿瘤患者的诊断/筛查标本中评估完整的 TCR-V(β)-R,以确定肿瘤特异性 TCR-V(β)蛋白表达。随后,对 17 例来自这些患者的少细胞标本(8 例 CSF,9 例 FNA)进行了简化的、患者特异性的 TCR-V(β)-R 评估,以分期和监测微小残留疾病(MRD)。包含 3 种抗 V(β)抗体(1 种肿瘤特异性和 2 种阴性对照)的单一鸡尾酒,结合其他有助于对非典型 T 细胞进行门控的抗体,对检测少细胞标本中的低水平肿瘤性 T 细胞受累具有高度的敏感性和特异性。这种 TCR-V(β)-R 策略在 T 细胞非霍奇金淋巴瘤患者的分期和评估 MRD 中具有重要价值。